Compare DoorDash Inc (DASH) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Heron Therapeutics Inc — how do they compare? DoorDash Inc trades at $197.5 (market cap $83.07B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: DoorDash Inc is far larger — about 1221.4× Heron Therapeutics Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Heron Therapeutics Inc for 35 Days on average.
| DASH | HRTX | |
|---|---|---|
Market Cap | $83.07B | $68.01M |
Volume | 3,242,567 | 1,891,941 |
Sector | Media | Health |
52-Week High | $275.44 | $1.49 |
52-Week Low | $146.60 | $0.27 |
Typical Hold Time | 59 Days | 35 Days |
Enterprise Value | $81.03B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $196.33, up 2.66% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent developments include AI-powered text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with 75% buy ratings and a $255.80 price target, representing 30% upside potential from current levels.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026, though net income may moderate to $841M. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and execution challenges in new initiatives. The stock trades at premium valuations (P/E 100.37) requiring sustained growth to justify current levels.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
